{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:06:12Z","timestamp":1784354772395,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Temozolomide (TMZ) concomitant with radiotherapy is the first-line treatment for glioblastoma. However, treatment resistance is frequently observed in patients. Cellular senescence (CSEN) induced by TMZ has been proposed to be one underlying mechanism resulting in resting cells, causing inflammation and possibly recurrences if senescent cells re-enter the cell cycle after treatment. Inhibition of the K<jats:sup>+<\/jats:sup>\u2009channels human ether-\u00e0-go-go type 1 (Eag1) and human ether-\u00e0-go-go-related gene (hERG) has shown promising effects in several tumor types including glioblastoma through growth inhibition and induction of apoptosis. In the present study, we analyzed the impact of hERG\/Eag1 inhibition on apoptosis and CSEN on its own and in combination with TMZ in a panel of human glioblastoma cell lines and primary glioblastoma cells. hERG\/Eag1 protein expression was determined by Western blotting and immunocytochemistry. Cytotoxicity of astemizole and terfenadine alone or in combination with TMZ was assessed by MTT assays. Apoptotic yields were determined by Annexin V\/propidium iodide staining, and CSEN was quantified by determining SA-\u03b2-galactosidase levels through flow cytometry. We observed a similar protein expression of hERG and Eag1 in all glioblastoma cell lines and primary glioblastoma cells. Astemizole and terfenadine were cytotoxic in glioblastoma cells at low micromolar concentrations (5\u201310\u00a0\u00b5M range) through induction of apoptosis. In combination with TMZ, both drugs synergistically sensitized glioblastoma cells to TMZ-induced apoptosis. Moreover, astemizole reduced significantly the TMZ-induced CSEN level, indicating its impact on CSEN induction. Here, we show for the first time that blocking hERG\/Eag1 channels in glioblastoma cells can relief TMZ-induced CSEN and synergistically ameliorates cytotoxicity through the induction of apoptosis.<\/jats:p>","DOI":"10.1007\/s00210-025-03955-w","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T19:33:27Z","timestamp":1742844807000},"page":"12267-12278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Apoptotic and senolytic effects of hERG\/Eag1 channel blockers in combination with temozolomide in human glioblastoma cells"],"prefix":"10.1007","volume":"398","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1213-3527","authenticated-orcid":false,"given":"Bodo","family":"Haas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inken","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"S\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wos-Maganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Beltzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kaina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"3955_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-18-1733","volume":"79","author":"D Aasland","year":"2019","unstructured":"Aasland D et al (2019) Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-kappaB. Cancer Res 79:99\u2013113. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1733","journal-title":"Cancer Res"},{"key":"3955_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ejca.2012.08.020","volume":"49","author":"Y Bai","year":"2013","unstructured":"Bai Y et al (2013) MiR-296\u20133p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer 49:710\u2013724. https:\/\/doi.org\/10.1016\/j.ejca.2012.08.020","journal-title":"Eur J Cancer"},{"key":"3955_CR3","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.3390\/cells11162588","volume":"11","author":"L Beltzig","year":"2022","unstructured":"Beltzig L, Christmann M, Kaina B (2022a) Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. Cells 11:2588. https:\/\/doi.org\/10.3390\/cells11162588","journal-title":"Cells"},{"key":"3955_CR4","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.3390\/cancers14092233","volume":"14","author":"L Beltzig","year":"2022","unstructured":"Beltzig L et al (2022b) Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. Cancers (Basel) 14:2233. https:\/\/doi.org\/10.3390\/cancers14092233","journal-title":"Cancers (Basel)"},{"key":"3955_CR5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1586\/ern.10.32","volume":"10","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC (2010) Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10:1537\u20131544. https:\/\/doi.org\/10.1586\/ern.10.32","journal-title":"Expert Rev Neurother"},{"key":"3955_CR6","first-page":"865","volume":"33","author":"LC Cunha","year":"2013","unstructured":"Cunha LC, Del Bel E, Pardo L, Stuhmer W, Titze DEAR (2013) RNA interference with EAG1 enhances interferon gamma injury to glioma cells in vitro. Anticancer Res 33:865\u2013870","journal-title":"Anticancer Res"},{"key":"3955_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s0223-5234(03)00012-6","volume":"38","author":"L Di","year":"2003","unstructured":"Di L, Kerns EH, Fan K, McConnell OJ, Carter GT (2003) High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38:223\u2013232. https:\/\/doi.org\/10.1016\/s0223-5234(03)00012-6","journal-title":"Eur J Med Chem"},{"key":"3955_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s43018-023-00626-8","volume":"4","author":"W Dong","year":"2023","unstructured":"Dong W et al (2023) A designer peptide against the EAG2-Kvbeta2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma. Nat Cancer 4:1418\u20131436. https:\/\/doi.org\/10.1038\/s43018-023-00626-8","journal-title":"Nat Cancer"},{"key":"3955_CR9","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1158\/0008-5472.CAN-08-3153","volume":"69","author":"N Eckstein","year":"2009","unstructured":"Eckstein N et al (2009) Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 69:2996\u20133003. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3153","journal-title":"Cancer Res"},{"key":"3955_CR10","doi-asserted-by":"publisher","unstructured":"Elias AF, Lin BC, Piggott BJ (2023) Ion Channels in Gliomas-From Molecular Basis to Treatment. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24032530","DOI":"10.3390\/ijms24032530"},{"key":"3955_CR11","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3:e00149. https:\/\/doi.org\/10.1002\/prp2.149","journal-title":"Pharmacol Res Perspect"},{"key":"3955_CR12","doi-asserted-by":"publisher","first-page":"ra78","DOI":"10.1126\/scisignal.2000511","volume":"2","author":"B Haas","year":"2009","unstructured":"Haas B et al (2009) Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesis. Sci Signal 2:ra78. https:\/\/doi.org\/10.1126\/scisignal.2000511","journal-title":"Sci Signal"},{"key":"3955_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12935-018-0565-4","volume":"18","author":"B Haas","year":"2018","unstructured":"Haas B et al (2018) Inhibition of the PI3K but not the MEK\/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell Int 18:69. https:\/\/doi.org\/10.1186\/s12935-018-0565-4","journal-title":"Cancer Cell Int"},{"key":"3955_CR14","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/ijms20071562","volume":"20","author":"Y He","year":"2019","unstructured":"He Y, Kaina B (2019) Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? Int J Mol Sci 20:1562. https:\/\/doi.org\/10.3390\/ijms20071562","journal-title":"Int J Mol Sci"},{"key":"3955_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188355","volume":"1873","author":"S He","year":"2020","unstructured":"He S et al (2020) HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential Biochim Biophys Acta Rev. Cancer 1873:188355. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188355","journal-title":"Cancer"},{"key":"3955_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1471-4159.2005.03583.x","volume":"96","author":"M Hermisson","year":"2006","unstructured":"Hermisson M et al (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96:766\u2013776. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03583.x","journal-title":"J Neurochem"},{"key":"3955_CR17","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1038\/cddis.2011.77","volume":"2","author":"J Jehle","year":"2011","unstructured":"Jehle J, Schweizer PA, Katus HA, Thomas D (2011) Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis 2:e193. https:\/\/doi.org\/10.1038\/cddis.2011.77","journal-title":"Cell Death Dis"},{"key":"3955_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3390\/jcm12237442","volume":"12","author":"B Kaina","year":"2023","unstructured":"Kaina B (2023) Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications. J Clin Med 12:744. https:\/\/doi.org\/10.3390\/jcm12237442","journal-title":"J Clin Med"},{"key":"3955_CR19","doi-asserted-by":"publisher","unstructured":"Komori T (2022) [The 2021 WHO Classification of Tumors, 5th edition, Central Nervous System Tumors: A Short Review]. Brain Nerve 74:803\u2013809. https:\/\/doi.org\/10.11477\/mf.1416202124","DOI":"10.11477\/mf.1416202124"},{"key":"3955_CR20","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1038\/cddis.2013.174","volume":"4","author":"K Lansu","year":"2013","unstructured":"Lansu K, Gentile S (2013) Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program. Cell Death Dis 4:e652. https:\/\/doi.org\/10.1038\/cddis.2013.174","journal-title":"Cell Death Dis"},{"key":"3955_CR21","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.bbamem.2014.12.016","volume":"1848","author":"E Lastraioli","year":"2015","unstructured":"Lastraioli E, Iorio J, Arcangeli A (2015) Ion channel expression as promising cancer biomarker. Biochim Biophys Acta 1848:2685\u20132702. https:\/\/doi.org\/10.1016\/j.bbamem.2014.12.016","journal-title":"Biochim Biophys Acta"},{"key":"3955_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3:198\u2013210. https:\/\/doi.org\/10.1016\/j.gendis.2016.04.007","journal-title":"Genes Dis"},{"key":"3955_CR23","doi-asserted-by":"publisher","first-page":"12272","DOI":"10.1038\/s41598-020-68473-6","volume":"10","author":"YJ Lee","year":"2020","unstructured":"Lee YJ, Seo HW, Baek JH, Lim SH, Hwang SG, Kim EH (2020) Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment. Sci Rep 10:12272. https:\/\/doi.org\/10.1038\/s41598-020-68473-6","journal-title":"Sci Rep"},{"key":"3955_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"3955_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.neuroscience.2008.05.019","volume":"155","author":"S Martin","year":"2008","unstructured":"Martin S, Lino de Oliveira C, Mello de Queiroz F, Pardo LA, Stuhmer W, Del Bel E (2008) Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neuroscience 155:833\u2013844. https:\/\/doi.org\/10.1016\/j.neuroscience.2008.05.019","journal-title":"Neuroscience"},{"key":"3955_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1186\/s12885-015-1848-y","volume":"15","author":"R Martinez","year":"2015","unstructured":"Martinez R, Stuhmer W, Martin S, Schell J, Reichmann A, Rohde V, Pardo L (2015) Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival. BMC Cancer 15:839. https:\/\/doi.org\/10.1186\/s12885-015-1848-y","journal-title":"BMC Cancer"},{"key":"3955_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.bjc.6602775","volume":"93","author":"A Masi","year":"2005","unstructured":"Masi A et al (2005) hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer 93:781\u2013792. https:\/\/doi.org\/10.1038\/sj.bjc.6602775","journal-title":"Br J Cancer"},{"issue":"Pt 1","key":"3955_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1469-7793.1998.049br.x","volume":"508","author":"R Meyer","year":"1998","unstructured":"Meyer R, Heinemann SH (1998) Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol 508(Pt 1):49\u201356. https:\/\/doi.org\/10.1111\/j.1469-7793.1998.049br.x","journal-title":"J Physiol"},{"key":"3955_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"Milanovic M et al (2018) Senescence-associated reprogramming promotes cancer stemness. Nature 553:96\u2013100. https:\/\/doi.org\/10.1038\/nature25167","journal-title":"Nature"},{"key":"3955_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1113\/jphysiol.1992.sp018938","volume":"445","author":"B Nilius","year":"1992","unstructured":"Nilius B, Wohlrab W (1992) Potassium channels and regulation of proliferation of human melanoma cells. J Physiol 445:537\u2013548. https:\/\/doi.org\/10.1113\/jphysiol.1992.sp018938","journal-title":"J Physiol"},{"key":"3955_CR31","doi-asserted-by":"publisher","first-page":"C1501","DOI":"10.1152\/ajpcell.1993.265.6.C1501","volume":"265","author":"B Nilius","year":"1993","unstructured":"Nilius B, Schwarz G, Droogmans G (1993) Control of intracellular calcium by membrane potential in human melanoma cells. Am J Physiol 265:C1501-1510. https:\/\/doi.org\/10.1152\/ajpcell.1993.265.6.C1501","journal-title":"Am J Physiol"},{"key":"3955_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbrc.2016.01.071","volume":"470","author":"R Ouchi","year":"2016","unstructured":"Ouchi R, Okabe S, Migita T, Nakano I, Seimiya H (2016) Senescence from glioma stem cell differentiation promotes tumor growth. Biochem Biophys Res Commun 470:275\u2013281. https:\/\/doi.org\/10.1016\/j.bbrc.2016.01.071","journal-title":"Biochem Biophys Res Commun"},{"key":"3955_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrc3635","volume":"14","author":"LA Pardo","year":"2014","unstructured":"Pardo LA, Stuhmer W (2014) The roles of K(+) channels in cancer. Nat Rev Cancer 14:39\u201348. https:\/\/doi.org\/10.1038\/nrc3635","journal-title":"Nat Rev Cancer"},{"key":"3955_CR34","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1093\/emboj\/18.20.5540","volume":"18","author":"LA Pardo","year":"1999","unstructured":"Pardo LA, del Camino D, Sanchez A, Alves F, Bruggemann A, Beckh S, Stuhmer W (1999) Oncogenic potential of EAG K(+) channels. EMBO J 18:5540\u20135547. https:\/\/doi.org\/10.1093\/emboj\/18.20.5540","journal-title":"EMBO J"},{"key":"3955_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.neulet.2004.07.001","volume":"368","author":"S Patt","year":"2004","unstructured":"Patt S et al (2004) Expression of ether a go-go potassium channels in human gliomas. Neurosci Lett 368:249\u2013253. https:\/\/doi.org\/10.1016\/j.neulet.2004.07.001","journal-title":"Neurosci Lett"},{"key":"3955_CR36","doi-asserted-by":"publisher","first-page":"e0140131","DOI":"10.1371\/journal.pone.01401314","volume":"10","author":"G Perazzoli","year":"2015","unstructured":"Perazzoli G et al (2015) Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One 10:e0140131. https:\/\/doi.org\/10.1371\/journal.pone.01401314","journal-title":"PLoS One"},{"key":"3955_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/1078-0432.CCR-15-3169","volume":"23","author":"KB Pointer","year":"2017","unstructured":"Pointer KB, Clark PA, Eliceiri KW, Salamat MS, Robertson GA, Kuo JS (2017) Administration of Non-Torsadogenic human Ether-a-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG-Expressing Glioblastoma Patients. Clin Cancer Res 23:73\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3169","journal-title":"Clin Cancer Res"},{"key":"3955_CR38","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M et al (2024) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021. Neuro Oncol 26:vi1\u2013vi85. https:\/\/doi.org\/10.1093\/neuonc\/noae145","journal-title":"Neuro Oncol"},{"key":"3955_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41698-023-00476-8","volume":"7","author":"C Riviere-Cazaux","year":"2023","unstructured":"Riviere-Cazaux C et al (2023) An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence NPJ Precis. Oncol 7:126. https:\/\/doi.org\/10.1038\/s41698-023-00476-8","journal-title":"Oncol"},{"key":"3955_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3233\/JAD-2010-1262","volume":"19","author":"LE Rojo","year":"2010","unstructured":"Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB (2010) Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer\u2019s disease. J Alzheimers Dis 19:573\u2013589. https:\/\/doi.org\/10.3233\/JAD-2010-1262","journal-title":"J Alzheimers Dis"},{"key":"3955_CR41","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.3892\/ol.2016.4992","volume":"12","author":"TT Sales","year":"2016","unstructured":"Sales TT, Resende FF, Chaves NL, Titze-De-Almeida SS, Bao SN, Brettas ML, Titze-De-Almeida R (2016) Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomide. Oncol Lett 12:2581\u20132589. https:\/\/doi.org\/10.3892\/ol.2016.4992","journal-title":"Oncol Lett"},{"key":"3955_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcpt.13515","volume":"128","author":"T Shugg","year":"2021","unstructured":"Shugg T, Dave N, Amarh E, Assiri AA, Pollok KE, Overholser BR (2021) Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma. Basic Clin Pharmacol Toxicol 128:357\u2013365. https:\/\/doi.org\/10.1111\/bcpt.13515","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3955_CR43","doi-asserted-by":"publisher","first-page":"e88164","DOI":"10.1371\/journal.pone.0088164","volume":"9","author":"I Staudacher","year":"2014","unstructured":"Staudacher I et al (2014) HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells. PLoS One 9:e88164. https:\/\/doi.org\/10.1371\/journal.pone.0088164","journal-title":"PLoS One"},{"key":"3955_CR44","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"3955_CR45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"3955_CR46","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/00207454.2014.986673","volume":"126","author":"AG Sun","year":"2016","unstructured":"Sun AG, Lin AQ, Huang SY, Huo D, Cong CH (2016) Identification of potential drugs for Parkinson\u2019s disease based on a sub-pathway method. Int J Neurosci 126:318\u2013325. https:\/\/doi.org\/10.3109\/00207454.2014.986673","journal-title":"Int J Neurosci"},{"key":"3955_CR47","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1172\/JCI64098","volume":"123","author":"T Tchkonia","year":"2013","unstructured":"Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL (2013) Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 123:966\u2013972. https:\/\/doi.org\/10.1172\/JCI64098","journal-title":"J Clin Invest"},{"key":"3955_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/med.21808","volume":"42","author":"Z Toplak","year":"2022","unstructured":"Toplak Z et al (2022) Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment. Med Res Rev 42:183\u2013226. https:\/\/doi.org\/10.1002\/med.21808","journal-title":"Med Res Rev"},{"key":"3955_CR49","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","volume":"92","author":"JI Vandenberg","year":"2012","unstructured":"Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP (2012) hERG K(+) channels: structure, function, and clinical significance. Physiol Rev 92:1393\u20131478. https:\/\/doi.org\/10.1152\/physrev.00036.2011","journal-title":"Physiol Rev"},{"key":"3955_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00232-016-9944-8","volume":"250","author":"X Wang","year":"2017","unstructured":"Wang X, Chen Y, Zhang Y, Guo S, Mo L, An H, Zhan Y (2017) Eag1 Voltage-Dependent Potassium Channels: Structure, Electrophysiological Characteristics, and Function in Cancer. J Membr Biol 250:123\u2013132. https:\/\/doi.org\/10.1007\/s00232-016-9944-8","journal-title":"J Membr Biol"},{"key":"3955_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s002329900135","volume":"154","author":"WF Wonderlin","year":"1996","unstructured":"Wonderlin WF, Strobl JS (1996) Potassium channels, proliferation and G1 progression. J Membr Biol 154:91\u2013107. https:\/\/doi.org\/10.1007\/s002329900135","journal-title":"J Membr Biol"},{"key":"3955_CR52","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/nrd2983","volume":"8","author":"H Wulff","year":"2009","unstructured":"Wulff H, Castle NA, Pardo LA (2009) Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8:982\u20131001. https:\/\/doi.org\/10.1038\/nrd2983","journal-title":"Nat Rev Drug Discov"},{"key":"3955_CR53","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/febs.16350","volume":"290","author":"L Zhang","year":"2023","unstructured":"Zhang L, Pitcher LE, Prahalad V, Niedernhofer LJ, Robbins PD (2023) Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J 290:1362\u20131383. https:\/\/doi.org\/10.1111\/febs.16350","journal-title":"FEBS J"},{"key":"3955_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12859-023-05180-9","volume":"24","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Song Y (2023) Integrated analysis of the voltage-gated potassium channel-associated gene KCNH2 across cancers. BMC Bioinformatics 24:51. https:\/\/doi.org\/10.1186\/s12859-023-05180-9","journal-title":"BMC Bioinformatics"},{"key":"3955_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2006.03.002","volume":"112","author":"BJ Zunkler","year":"2006","unstructured":"Zunkler BJ (2006) Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol Ther 112:12\u201337. https:\/\/doi.org\/10.1016\/j.pharmthera.2006.03.002","journal-title":"Pharmacol Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03955-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03955-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03955-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:37:50Z","timestamp":1758256670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03955-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3955"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03955-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing\u00a0nor financial and\u00a0non-financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The opinions mentioned throughout the following article are personal views of the authors and do not reflect an official position of the Federal Institute for Drugs and Medical Devices (BfArM).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}